U.S. Food and Drug Administration Center for Drug Evaluation and ResearchSkip navigation

CDER - Center for Drug Evaluation and Research Logo

Drug Information

CDER Home Site Information Comments and Feedback What's New CDER Navigation Bar

CDER ArchivesSpecific AudiencesCDER CalendarRegulatory InformationDrug InformationAbout CDERSide Navigational Buttons

Risk Management Public Workshop - Day 1
Risk Assessment in Drug and Biologic Development

April 9, 2003

AGENDA (updated 4/7/2003)

Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologic Evaluation and Research (CBER)


Moderator: 
Deborah Henderson
, Director, Office of Executive Programs, CDER

8:00 - 8:15 

Welcome and Introductions
Dr. Steven Galson, Deputy Director, CDER

8:15 - 10:15 

Session I -- Data Generation

  • FDA Presentation - Dr. Robert J. Meyer, Director, Office of Drug Evaluation II, CDER
  • Oral Presentations - Public Comment (preregistered)
    • Glenn Gormley, M.D, Ph.D., AstraZeneca, PhRMA
    • Judith Jones, M.D., Ph.D., The Degge Group for the International Society for Pharmacoepidemiology
    • Joanna Haas, M.D., MSc., Genzyme Corporation, Biotechnology Industry Organization
  • Panel Discussion and Q&As

10:15 - 10:30  Break

10:30 - 12:30 

Session II - Special Considerations

FDA Presentation - Dr. Robert Temple, Director, Office of Drug Evaluation I, CDER

  • Oral Presentations - Public Comment (preregistered)
    • Dr. Gary Stein, American Society of Health-System Pharmacists
    • Michael R. Cohen, RPh, MS, ScD, Institute for Safe Medication Practices
    • Penelope K. Manasco, M.D., First Genetic Trust
    • Anshu Vashishtha, M.D., Ph.D., Watson Pharmaceuticals
  • Panel Discussion and Q & As

12:30 - 1:45  Lunch

1:45 - 3:00 

Session III - Data Presentation/Analysis

  • FDA Presentation - Dr. Ellis Unger, Division of Clinical Trial Design and Analysis, CBER
  • Oral Presentations - Public Comment (preregistered)
    • Christy Chaung-Stein, Ph.D., Pharmaceia, PhRMA
    • Dr. Sidney Kahn, Pharmacovigilance & Risk Management, Inc.

3:00 - 3:15  Break

Oral Presentations (cont'd) - Public Comment (preregistered)

  • Dr. Paul Stolley, Public Citizen Health Research Group, 

Panel Discussion and Q & As

4:00 - 4:30  Closing Remarks - Dr. Robert Meyer


totop.gif (1525 bytes) Back to Top   Back Risk Management Public Workshop

FDA/Center for Drug Evaluation and Research
Posted: March 5, 2003, Updated April 7, 2003
Originator: OTCOM/DLIS
HTML by SJW, PKS